40172-04-1

Usage

Structure

A derivative of ethanol with a benzylamine group and a chlorine atom attached to the benzene ring

Usage

Commonly used in the pharmaceutical and chemical industries as a building block for the synthesis of various drugs and organic compounds

Applications

Potential applications in the development of new medications and as a reagent in organic synthesis, as well as in research and development activities for its structural and functional properties

Unique properties

Due to its chemical structure and functional groups, 2-(4-CHLORO-BENZYLAMINO)-ETHANOL possesses unique properties that make it valuable for a wide range of applications in various scientific and industrial fields.

Upstream product

• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 141-43-5 ethanolamine 
• 16327-95-0 p-chloro-N-benzilidine ethanolamine 
• 104-88-1 4-chlorobenzaldehyde 
• 622-95-7 4-chlorobenzyl bromide 

Downstream Products

• 105905-67-7 chloro-acetic acid-[(4-chloro-benzyl)-(2-hydroxy-ethyl)-amide] 
• 441314-95-0 N,N'-bis(p-chlorobenzyl)piperazine 
• 1018909-08-4 tert-butyl (2-azidoethyl)(4-chlorobenzyl)carbamate 
• 1018909-30-2 tert-butyl 4-chlorobenzyl(2'-(methylamino)ethyl)carbamate 
• 1018909-28-8 tert-butyl 4-chlorobenzyl(2'-oxoethyl)carbamate 
• 1018909-16-4 tert-butyl (2-aminoethyl)(4-chlorobenzyl)carbamate 
• 115-22-0 3-Hydroxy-3-methyl-2-butanone 
• 6317-28-8 3-(4-chlorobenzyl)oxazolidin-2-one 
• 1391074-47-7 1-(2-benzo[b]thiophen-3-yl-acetyl)-2-methyl-azetidine-2-carboxylic acid (4-chloro-benzyl)-(2-hydroxy-ethyl)-amide 
• 1397956-79-4 3-(((4-chlorobenzyl)(2-hydroxyethyl)amino)methyl)-5-(cyclohexylmethoxy)-4H-chromen-4-one 
• 1352732-59-2 N-tert-butyl-7-(4-chlorobenzyl)-3-oxo-2,3,5,6,7,8-hexahydrobenzo[i][1,4,7]dioxazecine-8-carboxamide 
• 1352732-55-8 5-(4-chlorobenzyl)-N-cyclohexyl-1-oxo-3,4,5,6-tetrahydrobenzo[f][1,4]oxazocine-6-carboxamide 
• 1003887-54-4 (R)-tert-butyl 2-((4-chlorobenzyl)(2-hydroxyethyl)carbamoyl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of benzimidazole analogs as a novel interleukin-5 inhibitors

A series of novel hydroxyethylaminomethylbenzimidazole analogs 5a-y were synthesized and evaluated for their IL-5 inhibitory activity using pro-B Y16 cell line. Among them, 2-(((4-(cyclohexylmethoxy)-1H-benzo[d]imidazol-2-yl)methyl)amino)butan-1-ol (5e, 94.3% inhibition at 30 μM, IC50 = 3.5 μM, cLogP = 4.132) and 3-cyclohexyl-2-(((4-(cyclohexylmethoxy)-1H-benzo[d]imidazol-2-yl)methyl)amino) propan-1-ol (5k, 94.7% inhibition at 30 μM, IC50 = 5.0 μM, cLogP = 6.253) showed the most potent inhibitory activity. The essential feature of SAR (Fig. 5) indicated that the chromenone ring can be replaced by a benzimidazole ring to maintain the inhibitory activity. In addition, the hydroxyethylaminomethyl group was suitable for the IL-5 inhibitory activity. Moreover, the hydrophobic substituents on carbon play an important role in the IL-5 inhibitory activity of these analogs. However, N-substituted analogs did not improve inhibitory activity. In addition, MTT assay of 5e and 5k with normal B lymphoblasts revealed that they had no significant effects on cell viability.

Ionic liquid-promoted three-component domino reaction of propargyl alcohols, carbon dioxide and 2-aminoethanols: A thermodynamically favorable synthesis of 2-oxazolidinones

To circumvent the thermodynamic limitation of the synthesis of oxazolidinones starting from 2-aminoethanols and CO2 and realize incorporation CO2 under atmospheric pressure, a protic ionic liquid-facilitated three-component reaction of propargyl alcohols, CO2 and 2-aminoethanols was developed to produce 2-oxazolidinones along with equal amount of α-hydroxyl ketones. The ionic liquid structure, reaction temperature and reaction time were in detail investigated. And 15 mol% 1,5,7-triazabicylo[4.4.0]dec-5-ene ([TBDH][TFE]) trifluoroethanol was found to be able to synergistically activate the substrate and CO2, thus catalyzing this cascade reaction under atmospheric CO2 pressure. By employing this task-specific ionic liquid as sustainable catalyst, 2-aminoethanols with different substituents were successfully transformed to 2-oxazolidinones with moderate to excellent yield after 12 h at 80 °C.

AgI/TMG-Promoted Cascade Reaction of Propargyl Alcohols, Carbon Dioxide, and 2-Aminoethanols to 2-Oxazolidinones

Chemical valorization of CO2 to access various value-added compounds has been a long-term and challenging objective from the viewpoint of sustainable chemistry. Herein, a one-pot three-component reaction of terminal propargyl alcohols, CO2, and 2-aminoethanols was developed for the synthesis of 2-oxazolidinones and an equal amount of α-hydroxyl ketones promoted by Ag2O/TMG (1,1,3,3-tetramethylguanidine) with a TON (turnover number) of up to 1260. By addition of terminal propargyl alcohol, the thermodynamic disadvantage of the conventional 2-aminoethanol/CO2 coupling was ameliorated. Mechanistic investigations including control experiments, DFT calculation, kinetic and NMR studies suggest that the reaction proceeds through a cascade pathway and TMG could activate propargyl alcohol and 2-aminoethanol through the formation of hydrogen bonds and also activate CO2.

THERAPEUTIC MACROLIDE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as "MC compounds"), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.

Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists

Monocyte infiltration is implicated in a variety of diseases including multiple myeloma, rheumatoid arthritis, and multiple sclerosis. C-C chemokine receptor 1 (CCR1) is a chemokine receptor that upon stimulation, particularly by macrophage inflammatory protein 1a (MIP-1a) and regulated on normal T-cell expressed and secreted (RANTES), mediates monocyte trafficking to sites of inflammation. High throughput screening of our combinatorial collection identified a novel, moderately potent CCR1 antagonist 3. The library hit 3 was optimized to the advanced lead compound 4. Compound 4 inhibited CCR1 mediated chemotaxis of monocytes with an IC50 of 20 nM. In addition, the compound was highly selective over other chemokine receptors. It had good microsomal stability when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CYP) inhibition. Pharmacokinetic evaluation of the compound in the rat showed good oral bioavailability.

PROLINE UREA CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION

Compounds of the formulae (I) and (II) are disclosed. The compounds are CCRl antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.

NOS INHIBITORS FOR TREATMENT OF MOTOR DEFICIT DISORDERS

The present invention relates to preventive therapies and treatments of motor deficit disorders. In particular, the present invention relates to compositions and methods for preventative therapy and treatment of motor deficit disorders, such as cerebral p

SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS

The invention claims compounds of the: (formula I); wherein: (formula II) is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18/